摘要
目的评价流感双解方治疗轻型流感病毒性肺炎的临床疗效和安全性。方法 52例流感病毒性肺炎患者随机分为中药组和对照组各26例,两组患者在基础治疗的同时,中药组卫气同病证口服流感双解1号方,气分热盛证口服流感双解2号方,每日1剂,疗程10天;对照组口服磷酸奥司他韦胶囊,每次75 mg,每日2次,治疗5天后停药,继续给予基础治疗,共10天。治疗后评价临床疗效、体温复常时间、平均起效时间、流感病毒抗原转阴率及肺炎胸片吸收情况,治疗前后进行中医证候评分及安全性指标观察。结果中药组临床疗效总有效率为92.3%,对照组为88.5%,两组比较差异无统计学意义(P>0.05)。两组患者治疗中、治疗后、随访时的中医证候评分均较治疗前明显下降(P<0.05)。两组患者平均起效时间、体温复常时间、肺炎胸片吸收评价和病毒抗原转阴率比较差异均无统计学意义(P>0.05)。两组患者发生不良事件严重程度分级均为轻度,不良事件与药物因果关系判断均为可疑或不可能。结论流感双解方可改善轻型流感病毒性肺炎患者临床症状,有效促进肺炎吸收和流感病毒抗原转阴,疗效与磷酸奥司他韦胶囊相当,且安全性好。
Objective To evaluate clinical curative effect and safety of Liugan Shuangjie Decoction （流感双解方） in treating mild influenza virus pneumonia. Methods Fifty-two 52 patients with influenza virus pneumonia were randomly divided into a Chinese medicine group and a control group, with 26 cases in each. Patients in two groups received basic treatment. Additionally, patients in the Chinese medicine group with disease involving both weifen and qifen syndrome took Liugan Shuangjie Decoction No. 1, while those with qifen heat excess syndrome took Liugan Shuangjie Decoction No. 2, one dose per day, for 10 days in total. The control group orally took Oseltamivir phosphate capsule 75 mg per time, twice per day, and drugs were stopped after 5-day treatment. Then the basic treatment was continually given for 10 days in total. After treatment, clinical curative effect, temperature recovery time, average onset time, negative conversion ratio of influenza virus antigen, and pneumonia absorption state on x-ray chest film were evaluated. Before and after treatment, Chinese syndrome grading was conducted and safety indexes were observed. Results The total clinical curative effect was 92.3% in the Chinese medical group, while 88.5% in the control group. There was no statistical significance in the difference between two groups （P 〉 0. 05 ）. In the middle of treatment, after treatment and in follow-up visit, Chinese syndrome scores of patients in two group remarkably decreased compared with that before treatment （ P 〈 0. 05 ）. There was no statistical significant difference in average onset time, temperature recovery time, evaluation of pneumonia absorption on x-ray chest film and negative conversion ratio of influenza virus antigen between the two groups （P 〉 0. 05 ）. Severity of adverse events of patients in two groups was all light. Causal relationship between adverse events and drugs was all judged to be doubtful or impossible. Conclusion Liugan Shuangjie monia, and effectively promote effect was equal to Oseltamivir Decoction could improve clinical symptoms of patients with mild influenza virus pneu- pneumonia absorption and negative conversion of influenza virus antigen. Its curative phosphate capsule and had good safety.
出处
《中医杂志》
CSCD
北大核心
2017年第2期128-132,共5页
Journal of Traditional Chinese Medicine
基金
"十二五"国家科技支撑计划(2013BAI02B08)
广东省高等学校人才引进专项资金(粤财教[2011]431号)
广州市科技计划项目(201400000002)
广东省中医院名中医药专家学术经验传承工作室建设项目
关键词
流感病毒性肺炎
流感双解方
卫气同病
气分热盛
磷酸奥司他韦
influenza virus pneumonia
Liugan Shuangjie Decoction
disease involving both weifen and qifen syndrome
qifen heat excess
Oseltamivir phosphate
